MediPoint: Infectious Disease Point of Care Testing - Global Analysis and Market Forecasts - GlobalData

MediPoint: Infectious Disease Point of Care Testing - Global Analysis and Market Forecasts

MediPoint: Infectious Disease Point of Care Testing - Global Analysis and Market Forecasts - GlobalData
MediPoint: Infectious Disease Point of Care Testing - Global Analysis and Market Forecasts
Published Sep 01, 2016
158 pages — Published Sep 01, 2016
Price US$ 5,995.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Point-of-care testing (POCT), as known as bedside/near-patient testing is one of the most rapidly growing areas in IVD.

Systems that are categorized as POC include the following -
- Disposable systems or devices, which vary from reagent test strips for a single analyte to multi-analyte reagent strips
- Small analyzers, usually hand-held devices
- Desktop analyzers are larger and include systems designed for use in clinics or small laboratories.

The infectious disease POCT space represents one of the fastest growing markets within the POC space. Just under $700 million in annual global sales and growth rate of 7.7% during the forecast period; the US, India and Brazil, are expected to show the fastest growth.A number of factors, such as the increasing prevalence of infectious diseases in developing countries, the rising usage of home-based POC devices, the expansion of the test menu, and technological advancements in molecular testing and lab-on-chip technology are stimulating the demand for infectious disease POCT.The rate of infectious disease POCT adoption will be moderated by the requirement for regulatory compliance, the pressure to control cost, and the need to demonstrate the clear clinical-cost benefits of POCT over central laboratory testing.

Highlights

Key Questions Answered

- What is the current and future infectious disease POCT market outlook in the developed and emerging markets? What trends are affecting the global market?
- What is the competitive landscape and market share of major players in the infectious disease POCT space across different regions?
- What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
- What are the unmet needs with the infectious disease POC tests currently on the market? How will emerging technologies such as molecular POC assays fulfil these unmet needs?
- What are the key factors influencing a physician to use infectious disease POC tests? What is physician perception and market outlook of these devices?
- What are the challenges and barriers that have hindered widespread adoption of infectious disease POC devices?

Scope

- Competitive assessment: Currently marketed infectious disease POC products and evolving competitive landscape
- In-depth analysis of unmet needs and adoption trends of different infectious disease POC devices
- Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
- Pipeline analysis: Emerging products and technologies.
- Annualized total infectious disease POCT market revenue by segment and market outlooks by country from 2013-2022.
- Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the global market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
- Identif

  
Source:
Document ID
GDME0237MAR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents810
  1.1 List of Tables133
  1.2 List of Figures162
2 Introduction182
  2.1 Catalyst181
  2.2 Related Reports191
3 Industry Overview2010
  3.1 Infectious Disease POCT Overview201
  3.2 Reimbursement Trends211
    3.2.1 US212
    3.2.2 France231
    3.2.3 Germany231
    3.2.4 Italy231
    3.2.5 Spain241
    3.2.6 UK241
    3.2.7 Japan241
    3.2.8 China251
    3.2.9 India251
    3.2.10 Brazil252
  3.3 Mergers, Acquisitions, and Key Partnerships273
4 Unmet Needs305
  4.1 Multiplexing301
  4.2 Sensitivity of Infectious Disease Immunoassays301
  4.3 Analytical Performance311
  4.4 Data Recording and Management321
  4.5 Infectious Disease POCT to Curb Usage of Antibiotics331
  4.6 Cost-Effectiveness Data331
  4.7 Primary Care Physician Needs341
5 Competitive Assessment3539
  5.1 Company Share Analysis351
    5.1.1 Global351
  5.2 Alere361
    5.2.1 Overview361
    5.2.2 Marketed Products Assessment373
    5.2.3 SWOT Analysis401
  5.3 Beckman Coulter401
    5.3.1 Overview401
    5.3.2 Marketed Products Assessment411
    5.3.3 SWOT Analysis421
  5.4 BioMerieux421
    5.4.1 Overview422
    5.4.2 Marketed Products Assessment441
    5.4.3 SWOT Analysis451
  5.5 Cepheid451
    5.5.1 Overview451
    5.5.2 Marketed Products Assessment462
    5.5.3 SWOT Analysis481
  5.6 Chembio Diagnostics491
    5.6.1 Overview491
    5.6.2 Marketed Products Assessment501
    5.6.3 SWOT Analysis511
  5.7 Meridian Bioscience511
    5.7.1 Overview512
    5.7.2 Marketed Products Assessment531
    5.7.3 SWOT Analysis541
  5.8 OraSure Technologies551
    5.8.1 Overview551
    5.8.2 Marketed Products Assessment561
    5.8.3 SWOT Analysis571
  5.9 Quidel571
    5.9.1 Overview572
    5.9.2 Marketed Products Assessment591
    5.9.3 SWOT Analysis601
  5.10 Roche Diagnostics611
    5.10.1 Overview611
    5.10.2 Marketed Products Assessment621
    5.10.3 SWOT Analysis621
  5.11 Trinity Biotech631
    5.11.1 Overview631
    5.11.2 Marketed Products Assessment641
    5.11.3 SWOT Analysis651
  5.12 Other Companies661
    5.12.1 North American Market Companies665
    5.12.2 European Market Companies712
    5.12.3 APAC and Other Markets Companies731
6 Pipeline Assessment749
  6.1 Overview741
  6.2 Early Development Pipeline753
  6.3 Pre-clinical Stage Pipeline781
  6.4 Clinical Stage Pipeline793
  6.5 Products in the Approval Process821
7 Market Outlook8359
  7.1 Test Trends831
    7.1.1 HIV POCT831
    7.1.2 Influenza POCT842
    7.1.3 HBV POCT862
    7.1.4 HCV POCT881
    7.1.5 C. difficile POCT891
  7.2 Market Dynamics901
    7.2.1 Driver: Fast Turnaround Time901
    7.2.2 Driver: Emergence of Molecular Infectious Disease POCT901
    7.2.3 Driver: Expansion POCT Menu911
    7.2.4 Driver: CLIA-Waived Status for POCT921
    7.2.5 Driver: Rising Prevalence of Diseases921
    7.2.6 Barriers: Management of POCT922
    7.2.7 Barriers: Competition with Laboratory Tests941
    7.2.8 Barriers: Reimbursement951
    7.2.9 Barriers: Regulatory Compliance961
  7.3 Market Outlook By Market Segment961
    7.3.1 Global Overview963
    7.3.2 HIV POCT992
    7.3.3 Influenza POCT1012
    7.3.4 HBV POCT1031
    7.3.5 HCV POCT1041
    7.3.6 C. difficile POCT1051
    7.3.7 Molecular POCT Analyzers1061
  7.4 Market Outlook By Geography1071
    7.4.1 Global Overview1074
    7.4.2 US1113
    7.4.3 France1143
    7.4.4 Germany1173
    7.4.5 Italy1203
    7.4.6 Spain1233
    7.4.7 UK1263
    7.4.8 Japan1293
    7.4.9 China1324
    7.4.10 India1363
    7.4.11 Brazil1393
8 Appendix14217
  8.1 Bibliography1424
  8.2 Abbreviations1465
  8.3 Report Methodology1514
    8.3.1 Overview1511
    8.3.2 Coverage1511
    8.3.3 Secondary Research1511
    8.3.4 Forecasting Methodology1521
    8.3.5 Primary Research Key Opinion Leader Interviews1531
    8.3.6 Primary Research Physician and Industry Interviews1541
    8.3.7 Expert Panel Validation1541
  8.4 About the Team1552
    8.4.1 Analysts1551
      8.4.1.1 Wenlu Hu, Bsc, Medical Devices Analyst (Author)1551
      8.4.1.2 Andrew Thompson, Ph.D., Managing Analyst and Product Manager1551
      8.4.1.3 Linda Tian, MSc, Managing Analyst, Medical Devices1561
    8.4.2 Tyler Fletcher, Global Head of Medical Devices1561
  8.5 About MediPoint1571
  8.6 About GlobalData1571
  8.7 Disclaimer1572

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "MediPoint: Infectious Disease Point of Care Testing - Global Analysis and Market Forecasts" Sep 01, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData/MediPoint-Infectious-Disease-Point-of-Care-Testing-Global-Analysis-and-Market-Forecasts-2085-24203>
  
APA:
GlobalData. (2016). MediPoint: Infectious Disease Point of Care Testing - Global Analysis and Market Forecasts Sep 01, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData/MediPoint-Infectious-Disease-Point-of-Care-Testing-Global-Analysis-and-Market-Forecasts-2085-24203>
  
US$ 5,995.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.